Business
Allied Corp. Strengthens IP and Pharma Strategy by Filing Provisional Patent for ALID-10 and ALID-11
Allied Corp. Strengthens IP and Pharma Strategy by Filing Provisional Patent for ALID-10 and ALID-11.
About this update from Allied Corp.
[{"type":"text","content":"\n KELOWNA, British Columbia, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Allied Corp. (\"Allied\") (OTCQB: ALID), an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues, is pleased to announce the filing of a new United States provisional patent application entitled “Compositions and Methods for Modulating Endocannabinoid Systems Activity and Treating Mental Health Disorders”.  The patent application covers Allied’s proprietary products, ALID-10 and ALID-11, as well as other novel cannabis derived compounds designed for superior pharmaceutical properties for treatment of PTSD and other mental disorders.  “The filing of this patent application supports our strategy of developing novel and differentiated cannabis derived pharmaceuticals for PTSD, our lead therapeutic indication,” said Calum Hughes, CEO of Allied.  “We are continuing to build a solid patent portfolio to maximize the value of ALID-10 and ALID-11, which are currently in Phase 1 human clinical trials.  Strengthening our patent portfolio is an important pillar in our pharmaceutical development strategy. After securing our Phase I clinical data and IMP number for commercialization, we intend to license this to a big pharma partner.\" For more information on Allied Corp., visit www.allied.health About Allied Corp.Allied Corp. is an international medical cannabis production company with a mission to address today’s medical issues by researching, creating and producing targeted cannabinoid health solutions. Allied Corp. uses an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique development of therapeutic products. Investor Relations:[email protected] Forward-Looking Statements: This press release contains “forward-looking information” within the meaning of applicable securities laws in Canada or “forward-looking statements” made pursuant to the “safe harbour” provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking information”). Forward-looking information may relate to ...